EA201690749A1 - Новые ингибиторы sglt1 - Google Patents

Новые ингибиторы sglt1

Info

Publication number
EA201690749A1
EA201690749A1 EA201690749A EA201690749A EA201690749A1 EA 201690749 A1 EA201690749 A1 EA 201690749A1 EA 201690749 A EA201690749 A EA 201690749A EA 201690749 A EA201690749 A EA 201690749A EA 201690749 A1 EA201690749 A1 EA 201690749A1
Authority
EA
Eurasian Patent Office
Prior art keywords
new
sglt1 inhibitors
sglt1
inhibitors
hydrate
Prior art date
Application number
EA201690749A
Other languages
English (en)
Other versions
EA028801B1 (ru
Inventor
Сьюзан Мари Реутцель-Эденс
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201690749A1 publication Critical patent/EA201690749A1/ru
Publication of EA028801B1 publication Critical patent/EA028801B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В настоящем изобретении предложено соединение формулы Iили его гидрат.
EA201690749A 2013-11-08 2014-10-30 Новые ингибиторы sglt1 EA028801B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361901488P 2013-11-08 2013-11-08
US61/901,488 2013-11-08
PCT/US2014/063161 WO2015069541A1 (en) 2013-11-08 2014-10-30 4-{4-[(1 e)-4-(2,9-diazaspiro[5.5]undec-2-yl)but-1 -en-1 -yl]-2-methylbenzyl}-5-(propan-2-yl)-1 h-pyrazol-3-yl beta-d- glucopyranoside acetate

Publications (2)

Publication Number Publication Date
EA201690749A1 true EA201690749A1 (ru) 2016-08-31
EA028801B1 EA028801B1 (ru) 2017-12-29

Family

ID=51982747

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690749A EA028801B1 (ru) 2013-11-08 2014-10-30 Новые ингибиторы sglt1

Country Status (35)

Country Link
US (1) US9573970B2 (ru)
EP (1) EP3066108B1 (ru)
JP (1) JP6197113B2 (ru)
KR (1) KR101858881B1 (ru)
CN (1) CN105705509B (ru)
AP (1) AP2016009180A0 (ru)
AR (2) AR098670A1 (ru)
AU (1) AU2014347065B2 (ru)
CA (1) CA2925128C (ru)
CL (1) CL2016000791A1 (ru)
CR (1) CR20160165A (ru)
CY (1) CY1121096T1 (ru)
DK (1) DK3066108T3 (ru)
DO (1) DOP2016000067A (ru)
EA (1) EA028801B1 (ru)
ES (1) ES2703944T3 (ru)
HR (1) HRP20182061T1 (ru)
IL (1) IL244899B (ru)
JO (1) JO3485B1 (ru)
LT (1) LT3066108T (ru)
MA (1) MA39019A1 (ru)
MX (1) MX368174B (ru)
MY (1) MY192242A (ru)
NZ (1) NZ718118A (ru)
PE (1) PE20160884A1 (ru)
PH (1) PH12016500851A1 (ru)
PL (1) PL3066108T3 (ru)
PT (1) PT3066108T (ru)
RS (1) RS58050B1 (ru)
SI (1) SI3066108T1 (ru)
SV (1) SV2016005190A (ru)
TN (1) TN2016000112A1 (ru)
TW (1) TWI655198B (ru)
UA (1) UA118767C2 (ru)
WO (1) WO2015069541A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201992726A1 (ru) * 2017-06-12 2020-04-23 Лингамед, Ллс Способ получения (s,s)-секоизоларицирезинола диглюкозида и (r,r)-секоизоларицирезинола диглюкозида
CN110054657B (zh) 2018-01-18 2021-06-29 亚宝药业集团股份有限公司 吡喃葡萄糖取代的吡唑化合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU782330B2 (en) 1999-08-31 2005-07-21 Kissei Pharmaceutical Co. Ltd. Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
ES2319263T3 (es) 2001-02-26 2009-05-06 Kissei Pharmaceutical Co., Ltd. Derivados de glucopiranosilooxipirazol y su utilizacion como medicamentos.
EP1400529A4 (en) 2001-05-30 2007-12-19 Kissei Pharmaceutical GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF
EP1544208B1 (en) * 2002-08-08 2010-05-26 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
ZA200501094B (en) * 2002-08-08 2006-10-25 Kissei Pharmaceutical Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
DE102004028241B4 (de) * 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
MX2008014512A (es) * 2006-05-19 2008-11-27 Taisho Pharma Co Ltd Compuesto de c-fenil glucitol para el tratamiento de diabetes.
CN101910189B (zh) 2007-12-27 2013-06-19 橘生药品工业株式会社 吡唑衍生物的单癸二酸盐
WO2010095768A1 (en) 2009-02-23 2010-08-26 Taisho Pharmaceutical Co., Ltd. 4 -isopropylphenyl glucitol compounds as sgltl inhibitors
BR112012007349A2 (pt) 2009-10-02 2019-09-24 Sanofi Sa uso de composto com atividade inibidora de sglt-1/sglt-2 para produção de medicamentos para tratamento de doenças ósseas.
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1

Also Published As

Publication number Publication date
LT3066108T (lt) 2019-01-25
HRP20182061T1 (hr) 2019-02-08
TW201609783A (zh) 2016-03-16
IL244899A0 (en) 2016-05-31
JP2016539099A (ja) 2016-12-15
JO3485B1 (ar) 2020-07-05
CN105705509A (zh) 2016-06-22
UA118767C2 (uk) 2019-03-11
TN2016000112A1 (en) 2017-07-05
CA2925128C (en) 2017-10-17
CL2016000791A1 (es) 2016-11-11
IL244899B (en) 2019-10-31
PL3066108T3 (pl) 2019-03-29
CN105705509B (zh) 2018-12-04
SV2016005190A (es) 2018-11-01
TWI655198B (zh) 2019-04-01
MX368174B (es) 2019-09-23
KR20160067157A (ko) 2016-06-13
DK3066108T3 (da) 2019-01-02
AU2014347065A1 (en) 2016-04-07
US9573970B2 (en) 2017-02-21
AU2014347065B2 (en) 2016-09-29
AP2016009180A0 (en) 2016-04-30
PH12016500851B1 (en) 2016-06-20
US20160215011A1 (en) 2016-07-28
EP3066108A1 (en) 2016-09-14
AR098670A1 (es) 2016-06-08
KR101858881B1 (ko) 2018-05-16
MA39019A1 (fr) 2017-04-28
CR20160165A (es) 2016-06-08
DOP2016000067A (es) 2016-04-15
PE20160884A1 (es) 2016-09-10
JP6197113B2 (ja) 2017-09-13
MY192242A (en) 2022-08-10
EA028801B1 (ru) 2017-12-29
SI3066108T1 (sl) 2018-12-31
CY1121096T1 (el) 2019-12-11
WO2015069541A1 (en) 2015-05-14
PH12016500851A1 (en) 2016-06-20
ES2703944T3 (es) 2019-03-13
MX2016005999A (es) 2016-07-22
CA2925128A1 (en) 2015-05-14
NZ718118A (en) 2017-11-24
AR124083A2 (es) 2023-02-08
RS58050B1 (sr) 2019-02-28
PT3066108T (pt) 2018-11-29
EP3066108B1 (en) 2018-10-24

Similar Documents

Publication Publication Date Title
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
CR20150507A (es) Inhibidores de histona desmetilasas
CY1119105T1 (el) Παραγωγα διπυραζολιου ως αναστολεις jak
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
PH12016500676A1 (en) Pyrimidine fgfr4 inhibitors
EA201891211A1 (ru) Ингибиторы cxcr2
TR201905829T4 (tr) Buzdolabı.
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
TR201906366T4 (tr) Polisiklik-karbamoilpiridon bileşiklerinin sentezi.
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
UY34654A (es) Inhibidores de la beta-secretasa
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
EA201791684A1 (ru) Селективные ингибиторы bace1
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
EA201592183A1 (ru) Ингибиторы bace
DK3544981T3 (da) Benzodiazoliumforbindelser som enac-inhibitorer
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
MX2015008829A (es) Momelotinib deuterado.
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
AR124083A2 (es) Nuevo inhibidor de sglt1
CY1119540T1 (el) Υποκατασταθεντα απο γλυκοπυρανοσυλιο παραγωγα ινδολο-ουριας και η χρηση τους ως αναστολεις sglt
MX2015012610A (es) Pacritinib deuterizado.
EA201791596A1 (ru) Пиразоловые соединения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM